array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(13) "Pharming B.V."
["slug"]=>
string(20) "00474-nl-pharming-bv"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/6f06b060-b806-43f2-addd-a605083bf776"
["description"]=>
string(987) "Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates."
["address_street"]=>
string(12) "Darwinweg 24"
["address_place"]=>
string(6) "Leiden"
["address_region"]=>
NULL
["founding_date"]=>
NULL
["website_domain"]=>
string(12) "pharming.com"
["website_url"]=>
string(24) "https://www.pharming.com"
["industry_codes"]=>
array(1) {
[0]=>
string(75) "Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified"
}
["employee_count"]=>
NULL
["article_count"]=>
int(51)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(43) "Pharming redeems 123 million euros in bonds"
["snippet_en"]=>
string(147) "Pharming has repaid 123 million euros in bonds with a term until 2025. The biotech company from Leiden reported this after trading hours on Friday."
["url"]=>
string(91) "https://www.iex.nl/Nieuws/794857/Pharming-lost-voor-123-miljoen-euro-aan-obligaties-af.aspx"
["image_url"]=>
NULL
["source"]=>
string(6) "iex.nl"
["publication_date"]=>
string(10) "2024-04-01"
["categories"]=>
array(0) {
}
}
[1]=>
array(7) {
["title_en"]=>
string(33) "Pharming completes bond placement"
["snippet_en"]=>
string(252) "Pharming Group has successfully placed a bond loan of 100 million euros. The biotech company announced this on Thursday afternoon, after the issue was announced before the stock market..."
["url"]=>
string(76) "https://www.iex.nl/Nieuws/794760/Pharming-rondt-plaatsing-obligaties-af.aspx"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/ef5c6715-0018-40a1-a488-cb77aa384ec7"
["source"]=>
string(6) "iex.nl"
["publication_date"]=>
string(10) "2024-04-01"
["categories"]=>
array(0) {
}
}
[2]=>
array(7) {
["title_en"]=>
string(70) "Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price"
["snippet_en"]=>
string(122) "With a price-to-sales (or "P/S") ratio of 3.4x Pharming Group N.V. ( AMS:PHARM ) may be sending very bullish signals at..."
["url"]=>
string(153) "https://simplywall.st/stocks/nl/pharmaceuticals-biotech/ams-pharm/pharming-group-shares/news/revenues-working-against-pharming-group-nvs-amspharm-share-p"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/fe08ec05-c725-4afc-b7ee-d83ae48c4c6d"
["source"]=>
string(13) "simplywall.st"
["publication_date"]=>
string(10) "2024-02-14"
["categories"]=>
array(3) {
[0]=>
string(15) "Market Movement"
[1]=>
string(24) "Stock Research & Ratings"
[2]=>
string(12) "Stock Market"
}
}
[3]=>
array(7) {
["title_en"]=>
string(56) "Readers Competition | Especially Nasdaq popular for 2024"
["snippet_en"]=>
string(139) "The annual readers' competition of Beleggers Belangen has once again produced a large number of well-known and lesser-known names for 2024."
["url"]=>
string(87) "https://www.beleggersbelangen.nl/2024/01/07/vooral-nasdaq-populair-in-lezerscompetitie/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/7b876958-7628-48ac-93e0-e74c9f02fe8d"
["source"]=>
string(20) "beleggersbelangen.nl"
["publication_date"]=>
string(10) "2024-01-11"
["categories"]=>
array(2) {
[0]=>
string(21) "Competitive Behaviour"
[1]=>
string(11) "Competition"
}
}
[4]=>
array(7) {
["title_en"]=>
string(84) "Pharming's share price rises by more than 9% thanks to higher than expected turnover"
["snippet_en"]=>
string(145) "Sales growth of 10% from medicine Ruconest is higher than the company expected. Investors react enthusiastically to the message and set course..."
["url"]=>
string(111) "https://fd.nl/financiele-markten/3693272/1502485/koers-pharming-stijgt-ruim-9-dankzij-hoger-dan-verwachte-omzet"
["image_url"]=>
NULL
["source"]=>
string(5) "fd.nl"
["publication_date"]=>
string(10) "2024-01-08"
["categories"]=>
array(5) {
[0]=>
string(25) "Business Model Resilience"
[1]=>
string(12) "Stock Market"
[2]=>
string(24) "Quarterly/Annual Figures"
[3]=>
string(15) "Market Movement"
[4]=>
string(9) "Investors"
}
}
[5]=>
array(7) {
["title_en"]=>
string(17) "TomThumb | IEX.nl"
["snippet_en"]=>
string(182) "IEX.nl is the investor platform in the Netherlands. Stay up to date with all relevant information about shares and other investment products. Investing - Price - Shares - Discussion."
["url"]=>
string(50) "https://www.iex.nl/Leden/1889443/KleinDuimpje.aspx"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/db424618-480e-4765-8a73-e7b49f525854"
["source"]=>
string(6) "iex.nl"
["publication_date"]=>
string(10) "2023-11-01"
["categories"]=>
array(6) {
[0]=>
string(18) "General Investment"
[1]=>
string(12) "Stock Market"
[2]=>
string(20) "Corporate Governance"
[3]=>
string(12) "Board Change"
[4]=>
string(18) "Board Compensation"
[5]=>
string(46) "Management of Legal and Regulatory Environment"
}
}
[6]=>
array(7) {
["title_en"]=>
string(75) "Pharming Group to report third quarter 2023 financial results on October 26"
["snippet_en"]=>
string(276) "Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023."
["url"]=>
string(81) "https://finance.yahoo.com/news/pharming-group-report-third-quarter-060000578.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/222fecfb-6b72-4556-9f3b-642d69c24b75"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2023-10-12"
["categories"]=>
array(5) {
[0]=>
string(12) "Stock Market"
[1]=>
string(31) "Financial Update/Profit Warning"
[2]=>
string(24) "Quarterly/Annual Figures"
[3]=>
string(18) "Financial Distress"
[4]=>
string(9) "Investors"
}
}
[7]=>
array(7) {
["title_en"]=>
string(71) "Pharming Group to convene Extraordinary General Meeting of Shareholders"
["snippet_en"]=>
string(203) "Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on Monday, September 25, 2023 at 14:00 CEST."
["url"]=>
string(90) "https://finance.yahoo.com/news/pharming-group-convene-extraordinary-general-050000970.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/f0cfb5a2-09c7-4042-afd0-564d0cc8c62c"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2023-08-14"
["categories"]=>
array(2) {
[0]=>
string(21) "Shareholders Feedback"
[1]=>
string(5) "Event"
}
}
[8]=>
array(7) {
["title_en"]=>
string(33) "Pharming has a new growth diamond"
["snippet_en"]=>
string(126) "Biotech company Pharming is doing well with the new drug Joenja. "A new drug that generates so much money so quickly is rare.""
["url"]=>
string(82) "https://www.bndestem.nl/economie/pharming-heeft-een-nieuwe-groeibriljant~abb657e5/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/5900fb2c-55ac-4e1e-9778-291248ffcc3d"
["source"]=>
string(11) "bndestem.nl"
["publication_date"]=>
string(10) "2023-08-07"
["categories"]=>
array(0) {
}
}
}
["category_annotations"]=>
array(27) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(12)
}
[1]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(7)
}
[2]=>
array(2) {
["name"]=>
string(10) "Insolvency"
["count"]=>
int(4)
}
[3]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(3)
}
[4]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(3)
}
[5]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(3)
}
[6]=>
array(2) {
["name"]=>
string(9) "Investors"
["count"]=>
int(2)
}
[7]=>
array(2) {
["name"]=>
string(21) "Financial Performance"
["count"]=>
int(2)
}
[8]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(2)
}
[9]=>
array(2) {
["name"]=>
string(10) "Executives"
["count"]=>
int(1)
}
[10]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(1)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(1)
}
[12]=>
array(2) {
["name"]=>
string(24) "Government Interventions"
["count"]=>
int(1)
}
[13]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(1)
}
[14]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(1)
}
[15]=>
array(2) {
["name"]=>
string(21) "Shareholders Feedback"
["count"]=>
int(1)
}
[16]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(1)
}
[17]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(1)
}
[18]=>
array(2) {
["name"]=>
string(9) "Valuation"
["count"]=>
int(1)
}
[19]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(1)
}
[20]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(1)
}
[21]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(1)
}
[22]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(1)
}
[23]=>
array(2) {
["name"]=>
string(5) "Debts"
["count"]=>
int(1)
}
[24]=>
array(2) {
["name"]=>
string(19) "Economic Conditions"
["count"]=>
int(1)
}
[25]=>
array(2) {
["name"]=>
string(7) "Economy"
["count"]=>
int(1)
}
[26]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(1)
}
}
}
00474-nl-pharming-bv
Pharming B.V.
Location
Founded
Website
https://www.pharming.com
Articles
51 Articles
Category
Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified
Description
Pharming is a global biopharmaceutical company that develops and commercializes innovative protein replacement therapies and precision medicines for rare diseases. They are committed to being a sustainable partner for all stakeholder groups, including patients, healthcare professionals, employees, and shareholders. Pharming is headquartered in Leiden, the Netherlands, with its U.S. headquarters in Warren, New Jersey. They are listed on the Amsterdam Euronext and Nasdaq exchanges. Their vision is to become the leading global rare disease company and their mission is to bring solutions to unserved rare disease patients through drug development and commercialization. They aim to transform their pipeline to include multiple commercialized products in multiple geographies and to expand their technology portfolio. The company culture at Pharming emphasizes teamwork, self-development, and results orientation. They participate in investor conferences and provide financial updates.
<span style="background-color: initial; letter-spacing: 0.01em;">Pharming Group has successfully placed a bond loan of 100 million euros. The biotech company announced this on Thursday afternoon, after the issue was announced before the stock market...
IEX.nl is the investor platform in the Netherlands. Stay up to date with all relevant information about shares and other investment products. Investing - Price - Shares - Discussion.
Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023.
Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on Monday, September 25, 2023 at 14:00 CEST.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
